Alzheimer's Disease

Wisconsin

28 Alzheimer's Disease Trials near Wisconsin

Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Piromelatine for Alzheimer's Disease

Milwaukee, Wisconsin
This trial tests piromelatine, a pill taken before bed, in people with mild Alzheimer's who lack a specific genetic variation. The goal is to see if it can improve brain function and slow down dementia progression.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:60 - 85

225 Participants Needed

AR1001 for Alzheimer's Disease

Wauwatosa, Wisconsin
This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90

1150 Participants Needed

Donanemab for Alzheimer's Disease

Waterloo, Iowa
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:65 - 80

2996 Participants Needed

Donanemab for Early Alzheimer's Disease

Waterloo, Iowa
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85

1736 Participants Needed

Leuprolide for Alzheimer's Disease

Madison, Wisconsin
The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of a cholinesterase inhibitor medication like donepezil. Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) compared to placebo on cognitive function, global function and plasma and neuroimaging biomarkers.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:60+
Sex:Female

180 Participants Needed

Anti-amyloid Immunotherapies for Alzheimer's Disease

Rochester, Minnesota
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:50 - 90

135 Participants Needed

UCB-J for Alzheimer's Disease

Madison, Wisconsin
The overarching goal of this project is to use \[C-11\]UCB-J to obtain spatial information on neuronal synapse abundance and inform Alzheimer's disease (AD) progression. The investigators propose to collect longitudinal amyloid, tau, and Synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) in participants in the Wisconsin Alzheimer's Disease Research Center (ADRC) and Wisconsin Registry for Alzheimer's Prevention (WRAP) across the clinical stages of AD, including cognitively unimpaired biomarker negative, unimpaired biomarker positive, mild cognitive impairment (MCI), and dementia due to AD.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 89

102 Participants Needed

Senolytics for Alzheimer's Disease

Rochester, Minnesota
This trial is testing a combination of Dasatinib, a cancer drug, and Quercetin, a plant compound, to help people over 55 with memory problems or Alzheimer's disease. The goal is to see if these drugs can safely remove damaged cells in the brain. By doing so, it might slow down or improve the symptoms of Alzheimer's disease. Dasatinib plus quercetin has been previously tested in an early-stage Alzheimer's disease study.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 1, 2
Age:55+

20 Participants Needed

CT1812 for Early Alzheimer's Disease

Madison, Wisconsin
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 85

540 Participants Needed

Neuroinflammation Imaging for Alzheimer's Disease

Rochester, Minnesota
This trial uses a special brain scan with a new substance to highlight brain inflammation. It targets people with Alzheimer's Disease and those with brain issues. The scan helps doctors see inflammation in the brain.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:60 - 90

100 Participants Needed

BMS-984923 for Alzheimer's Disease

West Bend, Wisconsin
This trial tests a new drug, BMS-984923, in healthy older adults and early Alzheimer's patients. It aims to see if the drug is safe and can help restore brain cell connections, measured by PET scans.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:50 - 80

50 Participants Needed

ION269 for Down Syndrome at Risk of Alzheimer's Disease

Madison, Wisconsin
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:35 - 55

30 Participants Needed

LY3954068 for Alzheimer's Disease

Milwaukee, Wisconsin
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid. The study will last up to approximately 45 weeks for Part A, and, if conducted, 73 weeks for Part B, including the screening period. If the optional bridging period is conducted, participants in Part A could be enrolled in the separate potential study for up to approximately 96 weeks, including the screening period.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:50 - 85

32 Participants Needed

Care Partner Assessment Tool for Dementia

Madison, Wisconsin
The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they go home from the hospital. Participants will be a care partner ('family member or friend') who provides unpaid care to a hospitalized adult relative or partner to help them take care of themselves because of dementia. Participants can expect to be in this study for 14 days.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

128 Participants Needed

MR Evaluation for Brain Health

Rochester, Minnesota
The Researchers are trying to test a MR imaging method for detection of Cerebral Spinal Fluid (CSF) flow in the brain to help diagnosis and better understand diseases that affect brain function.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

50 Participants Needed

Molecular and Structural Imaging for Alzheimer's Disease

Rochester, Minnesota
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 80

60 Participants Needed

Caregiver Support Technology for Dementia

Rochester, Minnesota
This research is being done to develop a unique matching process for caregivers of persons living with dementia, such as Alzheimer's disease, Lewy body dementia, frontotemporal degeneration, or other dementia syndromes. Dementia caregivers often assume greater caregiving burden than do non-dementia caregivers, and the caregiving duration tends to be longer. Many caregivers do not have the adequate support they need. Peer-to-peer support has been shown to improve quality of life, more engagement with services, improve caregiver health, and reduce hospitalizations in the person they are caring for. This study will help determine whether caregivers of persons with dementia would find a technology-based caregiver matching program valuable for the purpose of emotional support.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

355 Participants Needed

Dysphagia Therapy for Alzheimer's Disease

Madison, Wisconsin
This trial tests a saliva gel and tongue exercises to help people with Alzheimer's who have trouble swallowing. These patients are at risk of pneumonia because they can't swallow well. The saliva gel keeps their mouth moist, and the exercises make their tongue stronger to help with swallowing.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 99

152 Participants Needed

Novel Healthcare Approaches for Delirium in Elders

Madison, Wisconsin
The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following: 1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity. 2. To compare the effectiveness of FAM-HELP and HELP in improving patient- and family-reported outcomes. 3. To explore the implementation context, process, and outcomes of the FAM-HELP program in diverse hospital settings.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:70+

3000 Participants Needed

Brain Amyloid Imaging for Alzheimer's Disease

Rochester, Minnesota
This trial uses a special brain scan to see harmful buildups in the brain. It targets both healthy people and those with brain diseases to understand how well the scan works.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 4
Age:30 - 100

8000 Participants Needed

Why Other Patients Applied

"I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

WU
Healthy Volunteer PatientAge: 76

"I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

AH
Dementia PatientAge: 64

"I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

VL
Alzheimer's PatientAge: 71

"I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

OF
Alzheimer's Disease PatientAge: 65

"I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

EK
Mild Cognitive Impairment PatientAge: 72

BMS-986446 for Early Alzheimer's Disease

Madison, Wisconsin
This trial is testing a new medication called BMS-986446 in people with early Alzheimer's disease. The medication is designed to target harmful proteins in the brain to slow down the disease. Researchers are checking if it works well and is safe for patients.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80

475 Participants Needed

Tau Tracer Comparison for Alzheimer's Disease

Rochester, Minnesota
This trial uses special imaging agents to help visualize harmful brain proteins in people at risk of Alzheimer's disease. The agents make these proteins glow during scans, allowing doctors to see them clearly and monitor the disease.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:50 - 90

620 Participants Needed

Nicotine Patch for Mild Cognitive Impairment

Madison, Wisconsin
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 90

380 Participants Needed

BMS-984923 for Drug Interaction

West Bend, Wisconsin
The goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together. Most drugs are broken down and cleared in the body via cytochrome P450 enzymes in the liver. The metabolism and clearance of certain drugs can be affected by other drugs when dosed together. To evaluate the impact of BMS-984923 on the clearance of other medications, we will investigate three known pathways which may be impacted by BMS-984923. In this study participants will take one dose of the three known medications, midazolam, caffeine and dextromethorphan together. These drugs are known to be cleared by different cytochrome P450 enzymes. Blood will be collected to evaluate the exposure and clearance of these medications and their primary metabolites. Study participants will then be administered BMS-984923 for 18-days. On the 18th Day of BMS-984923 dosing, participants will again be co-administering midazolam, caffeine and dextromethorphan. Blood will be collected again, and the concentration of each drug will be measured. We will learn in this study if BMS-984923 changes the exposure and metabolism of the known drugs. These results will inform how BMS-984923 can be administered to patients who take multiple medications.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 50

36 Participants Needed

Tau PET Imaging for Cognitive Impairment

Rochester, Minnesota
The researchers are trying to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:30+

240 Participants Needed

ECT for Dementia

Rochester, Minnesota
This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:40+

50 Participants Needed

AVP-786 for Agitation in Alzheimer's Disease

Waukesha, Wisconsin
This trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:50 - 90

1197 Participants Needed

OTC Hearing Aid for Cognitive Impairment

Madison, Wisconsin
The goal of this study is to better understand if, in patients with mild to moderate hearing loss who are also experiencing mild cognitive impairment (MCI) or Alzheimer's disease and related dementias (ADRD), Over-the-Counter (OTC) hearing aids: 1. improve communication 2. Whether the magnitude of benefit depends on the patient's level of cognitive disability, 3. Whether alternative remediation (such as targeted communication strategies) offer similar benefits. Participants and a communication partner will be randomized into an OTC first or Communication Strategies first arm, where participants will receive communication strategy information customized for those with cognitive impairment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:60 - 90

50 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Alzheimer's Disease clinical trials in Wisconsin pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Alzheimer's Disease clinical trials in Wisconsin work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Alzheimer's Disease trials in Wisconsin 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Wisconsin for Alzheimer's Disease is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Wisconsin several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Alzheimer's Disease medical study in Wisconsin?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Alzheimer's Disease clinical trials in Wisconsin?

Most recently, we added Anti-amyloid Immunotherapies for Alzheimer's Disease, ION269 for Down Syndrome at Risk of Alzheimer's Disease and BMS-984923 for Drug Interaction to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Prostate Cancer Clinical Trials near San Antonio, TX

Top Clinical Trials near Friendswood, TX

182 Clinical Trials near Belvidere, NJ

Top Clinical Trials near Kerrville, TX

Top Autism Clinical Trials near Miami, FL

Top Small Cell Lung Cancer Clinical Trials

Top Clinical Trials near Banning, CA

19 Weight Loss Trials near New York, NY

46 Psoriasis Trials near Chicago, IL

6 Weight Loss Trials near Austin, TX

Top Clinical Trials near Clyde, NC

212 Clinical Trials near Boiling Springs, SC

By Trial

Pegcetacoplan for Age-Related Macular Degeneration

Venetoclax + CLAG-M for Acute Myeloid Leukemia

Stem Cell Therapy for Spina Bifida

Digital Cognitive Behavioral Therapy with Coaching for Insomnia

Targeted Therapy for Solid Tumors

CPX-351 vs CLAG-M for Acute Myeloid Leukemia

Gene Therapy for Neuronal Ceroid Lipofuscinosis

HCB101 for Cancer

P4 Diagnostic Tool for Pancreatic Cancer

Cognitive Behavioral Therapy for Body Image Distress in Head and Neck Cancer Survivors

ctDNA Testing for Oropharyngeal Cancer

BST-236 + Venetoclax for Acute Myeloid Leukemia

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial